ADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
References
Sources used in this report
SEC APISEC submissions JSON2026-05-14 · Issuer identity, ticker, exchange, CIK, SIC, filing recency, and latest filing paths.SEC APISEC companyfacts JSON2026-05-14 · XBRL cross-check path for entity name and revenue facts.SEC filingFY2025 Form 10-K2026-03-10 · Business model, ZYNLONTA approvals, clinical programs, FY2025 results, restructuring, competition, manufacturing, IP, liquidity, debt, and royalty obligations.SEC filingQ1 2026 Form 10-Q2026-05-04 · Latest quarterly financial statements, cash, operating cash flow, liabilities, warrants, debt, royalty obligation, and share counts.Company release furnished to SECQ1 2026 earnings release2026-05-04 · Q1 product revenue, cash runway, LOTIS-5 and LOTIS-7 timing, adjusted expense, adjusted net loss, and management commentary.Company release furnished to SECFY2025 earnings release2026-03-10 · Annual results, product revenue, operating update, and management context.SEC governance filing2026 definitive proxy statement2026-04-20 · Board, executive, annual meeting, governance, and compensation evidence.SEC filingForm S-3 registration statement2026-03-10 · Capital markets shelf context and issuer securities evidence.